Mitochondrial protein-targeting engineered deubiquitinating enzymes and methods of use thereof

JP2023549167A5Inactive Publication Date: 2024-11-12FLUX THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023527966
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-06
Filing Date
2021-11-05
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Provided herein is a fusion protein comprising an effector domain comprising a catalytic domain of a deubiquitinase, or a functional fragment or variant thereof; and a targeting domain comprising a moiety that specifically binds to a mitochondrial protein. Also provided herein are methods of using the fusion protein to treat diseases, including genetic diseases.
Need to check novelty before this filing date? Find Prior Art

Claims

1. a. an effector domain comprising a catalytic domain of a deubiquitinase, or a functional fragment or variant thereof, b. A targeting domain that includes a targeting moiety that specifically binds to a mitochondrial protein. an effector domain operably linked to A nucleic acid molecule encoding a fusion protein comprising:

2. 2. The nucleic acid molecule of claim 1, wherein the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 80, 1-79, 81-112, or 418.

3. 2. The nucleic acid molecule of claim 1, wherein the catalytic domain comprises a catalytic domain derived from a deubiquitinase that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 80, 1-79, 81-112, or 418.

4. 2. The nucleic acid molecule of claim 1, wherein the catalytic domain comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 270, 113-220, or 419.

5. The nucleic acid molecule of claim 1 , wherein the portion that specifically binds to a mitochondrial protein comprises an antibody, or a functional fragment or functional variant thereof.

6. The nucleic acid molecule of claim 5 , wherein the antibody, or functional fragment or functional variant thereof, comprises a VHH.

7. 2. The nucleic acid molecule of claim 1, wherein the mitochondrial protein is dynamin-like 120 kDa protein (OPA1), protoporphyrinogen oxidase (PPOX), frataxin (FXN), DNA polymerase subunit gamma-1 (POLG), mitochondrial cytochrome c oxidase subunit 6A2 (COX6A2), ubiquinol-cytochrome-c reductase complex assembly factor 2 (UQCC2), or complex III assembly factor LYRM7 (LYRM7).

8. 2. The nucleic acid molecule of claim 1, wherein the mitochondrial protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 221-224 or 271-273.

9. The nucleic acid molecule of claim 1 , wherein the effector domain is indirectly operably linked to the targeting domain via a peptide linker.

10. The nucleic acid molecule of claim 1 which is a DNA molecule or an RNA molecule.

11. A vector comprising the nucleic acid molecule described in claim 1.

12. The vector of claim 11 which is a plasmid or a viral vector.

13. A viral particle containing the nucleic acid described in claim 1.

14. A pharmaceutical composition comprising the nucleic acid molecule of claim 1 and an excipient.

15. A pharmaceutical composition for treating a genetic disease, comprising the nucleic acid molecule described in claim 1.

16. 16. The pharmaceutical composition of claim 15, wherein the disease is selected from the group consisting of optic atrophy 1, variegate porphyria, Friedreich's ataxia, Alpers syndrome, mitochondrial complex IV deficiency karyotype 18 (MC4DN18), mitochondrial complex III deficiency karyotype 7 (MC3DN7), and mitochondrial complex III deficiency karyotype 8 (MC3DN8).

17. a. the target mitochondrial protein is OPA1 and the disease is optic atrophy 1; b. the target mitochondrial protein is PPOX and the disease is variegate porphyria; c. the target mitochondrial protein is FXN and the disease is Friedreich's ataxia; d. the target mitochondrial protein is POLG and the disease is Alpers syndrome; e. the target mitochondrial protein is COX6A2 and the disease is mitochondrial complex IV deficiency karyotype 18 (MC4DN18); f. the target mitochondrial protein is UQCC2 and the disease is mitochondrial complex III deficiency karyotype 7 (MC3DN7); or g. The target mitochondrial protein is LYRM7 and the disease is mitochondrial complex III deficiency karyotype 8 (MC3DN8); 16. The pharmaceutical composition of claim 15.

18. The pharmaceutical composition of claim 15, wherein the disease is a haploinsufficiency disease.